Nuclear Medicine ExplainedNM Explained
LearnAnimationsBoard ReviewToolsCalendar
Review
TREN

Settings and progress transfer · Help · About · AI and Claude · Legal

For educational purposes only; not a clinical decision tool.

Solve questions (27)

Contents

  1. 7.1 Annihilation Physics and Coincidence Detection
  2. 7.1.1 Positron Emission and Annihilation
  3. 7.1.2 Coincidence Detection
  4. 7.1.3 Types of Coincidence
  5. 7.1.4 Coincidence Timing Window
  6. 7.2 PET Detector Materials and Design
  7. 7.2.1 Scintillation Crystals
  8. 7.2.2 Detector Design
  9. 7.2.3 Photomultiplier Tube (PMT) and SiPM
  10. 7.3 TOF-PET (Time of Flight)
  11. 7.3.1 TOF Principle
  12. 7.3.2 Effect of TOF on Image Quality
  13. 7.3.3 TOF Resolution and Clinical Advantages
  14. 7.4 PET/CT Acquisition and Protocols
  15. 7.4.1 PET/CT System Design
  16. 7.4.2 2D vs 3D Acquisition
  17. 7.4.3 CT Attenuation Correction (CTAC)
  18. 7.4.4 FDG PET/CT Patient Preparation and Protocol
  19. 7.4.5 PET/CT Artefacts
  20. 7.4.6 Digital PET and Long Axial Field-of-View (LAFOV) PET
  21. 7.5 PET/MR: Technical Features and Advantages
  22. 7.5.1 PET/MR System Design
  23. 7.5.2 MR-Based Attenuation Correction (MRAC)
  24. 7.5.3 Advantages and Limitations of PET/MR
  25. 7.5.4 Clinical Applications of PET/MR
  26. 7.6 SUV Calculation and Quantitative Analysis
  27. 7.6.1 Definition and Formula of SUV
  28. 7.6.2 SUV Variants
  29. 7.6.3 Factors Affecting SUV
  30. 7.6.4 Other Quantitative Parameters
  31. 7.7 The CT Component of Hybrid Systems: Basic Principles
  32. 7.7.1 CT Reconstruction
  33. 7.7.2 CT Dosimetry and Dose Reduction
  34. 7.7.3 Metal Artefact and Photon-Counting CT
  35. 7.8 The MR Component of PET/MR: Basic Principles
  36. 7.8.1 Nuclear Magnetic Resonance and Image Formation
  37. 7.8.2 MR Scanner Components
  38. 7.9 Comparison of Imaging Modalities
  39. Key Points for the Board
  40. Current guidelines on this chapter's topics
← Back‹ Chapter 6Chapter 8 ›

Chapter 07Basic sciencesLast reviewed: 14 Nov 2026 · What's new

PET/CT and PET/MR

This chapter's English text is a draft translation (prepared with Claude and checked against a terminology glossary and automatic checks); specialist review is in progress. Please report errors with the feedback button.

Solve questions (27) →
Contents
  1. 7.1 Annihilation Physics and Coincidence Detection
  2. 7.1.1 Positron Emission and Annihilation
  3. 7.1.2 Coincidence Detection
  4. 7.1.3 Types of Coincidence
  5. 7.1.4 Coincidence Timing Window
  6. 7.2 PET Detector Materials and Design
  7. 7.2.1 Scintillation Crystals
  8. 7.2.2 Detector Design
  9. 7.2.3 Photomultiplier Tube (PMT) and SiPM
  10. 7.3 TOF-PET (Time of Flight)
  11. 7.3.1 TOF Principle
  12. 7.3.2 Effect of TOF on Image Quality
  13. 7.3.3 TOF Resolution and Clinical Advantages
  14. 7.4 PET/CT Acquisition and Protocols
  15. 7.4.1 PET/CT System Design
  16. 7.4.2 2D vs 3D Acquisition
  17. 7.4.3 CT Attenuation Correction (CTAC)
  18. 7.4.4 FDG PET/CT Patient Preparation and Protocol
  19. 7.4.5 PET/CT Artefacts
  20. 7.4.6 Digital PET and Long Axial Field-of-View (LAFOV) PET
  21. 7.5 PET/MR: Technical Features and Advantages
  22. 7.5.1 PET/MR System Design
  23. 7.5.2 MR-Based Attenuation Correction (MRAC)
  24. 7.5.3 Advantages and Limitations of PET/MR
  25. 7.5.4 Clinical Applications of PET/MR
  26. 7.6 SUV Calculation and Quantitative Analysis
  27. 7.6.1 Definition and Formula of SUV
  28. 7.6.2 SUV Variants
  29. 7.6.3 Factors Affecting SUV
  30. 7.6.4 Other Quantitative Parameters
  31. 7.7 The CT Component of Hybrid Systems: Basic Principles
  32. 7.7.1 CT Reconstruction
  33. 7.7.2 CT Dosimetry and Dose Reduction
  34. 7.7.3 Metal Artefact and Photon-Counting CT
  35. 7.8 The MR Component of PET/MR: Basic Principles
  36. 7.8.1 Nuclear Magnetic Resonance and Image Formation
  37. 7.8.2 MR Scanner Components
  38. 7.9 Comparison of Imaging Modalities
  39. Key Points for the Board
  40. Current guidelines on this chapter's topics
Learning objectives and modules4 modules · about 3 h 5 min

Learning objectives

After this chapter you will be able to:

  • Explain how positron range, annihilation and non-collinearity limit PET resolution.
  • Distinguish true, scattered and random coincidences and explain how they relate to the coincidence window and activity.
  • Compare PET crystals and detector designs; explain the contribution of TOF to image quality.
  • Explain the PET/CT acquisition protocol and CT-based attenuation correction, with its limits including respiratory misregistration.
  • Calculate SUV and its derivatives (SUVmax, SUVpeak, SUL, MTV, TLG) and list the factors that affect them.
  • Compare the technical features of PET/MR, the limits of MR-based attenuation correction and its advantages over PET/CT.

Modules

The chapter is divided into study modules without changing the order of the text: read, watch the animations, then answer the questions linked to those headings.

  1. Module 17.1–7.3 Annihilation Physics and Coincidence Detection · PET Detector Materials and Design · TOF-PET (Time of Flight)1 h · 5 animations · 17 questionsAnswer the questions →
  2. Module 27.4 PET/CT Acquisition and Protocols45 min · 2 animations · 17 questionsAnswer the questions →
  3. Module 37.5–7.6 PET/MR: Technical Features and Advantages · SUV Calculation and Quantitative Analysis45 min · 1 animation · 18 questionsAnswer the questions →
  4. Module 47.7–7.9 The CT Component of Hybrid Systems: Basic Principles · The MR Component of PET/MR: Basic Principles · Comparison of Imaging Modalities · Key Points for the Board35 min · 7 questionsAnswer the questions →

Times are estimates: 130 words per minute, 3 min per animation, 1.5 min per question.

Tip cards (55) →

MOST FREQUENTLY ASKED IN THIS CHAPTER

✓
PET/CT ~2001 (Townsend); CT replaced the Ge-68 transmission scan, which took up to 15 min
✓
TOF routine since 2006; LAFOV 1-2 m → ~1-2 mSv or <5 min whole body
✓
Gating: list mode; cardiac → ECG, respiratory → pneumatic belt
✓
PET/MR: Siemens 2011 (APD, no TOF), GE 2014 (SiPM, with TOF)
✓
DPC: SiPM microcell binary output; energy = number of cells fired
✓
MR coils and the table also contribute to 511 keV attenuation; CT-derived µ map in the phantom
✓
CTDI (16/32 cm phantom, mGy) ≠ patient dose; DLP = CTDI × length

7.1 Annihilation Physics and Coincidence Detection

7.1.1 Positron Emission and Annihilation4 questions

PET (Positron Emission Tomography) is a molecular imaging method using positron-emitting radionuclides. Its basic physical principle is based on positron-electron annihilation.

Positron emission:

•
In proton-rich (neutron-poor) nuclei a proton is converted into a neutron, a positron and a neutrino: p → n + β+ + νe
•
Threshold energy for positron emission: 1.022 MeV (2 × 0.511 MeV = 2 × electron mass)
•
The positron is the antiparticle of the electron: same mass, opposite charge (+1)
•
Process competing with positron emission: Electron capture (EC) → both reduce Z by 1 (see Section 2.2)
BOARD TIP
▸
The threshold energy for positron emission is 1.022 MeV. If the decay energy is <1.022 MeV, only electron capture occurs and there is no positron emission. If the board exam asks "why do some proton-rich radionuclides not emit positrons?" → decay energy <1.022 MeV.

Positron range:

•
After emission the positron loses its kinetic energy by interacting with the surrounding matter
•
The positron, having lost its energy, combines with an electron → annihilation
•
Positron range is one of the physical factors limiting the spatial resolution of PET
•
The range depends on the maximum positron energy of the radionuclide:
•
F-18: Emax = 0.634 MeV → mean range ~0.6 mm → shortest range → best resolution
•
C-11: Emax = 0.960 MeV → mean range ~1.1 mm
•
N-13: Emax = 1.198 MeV → mean range ~1.5 mm
•
O-15: Emax = 1.732 MeV → mean range ~2.5 mm
•
Ga-68: Emax = 1.899 MeV → mean range ~2.9 mm
•
Rb-82: Emax = 3.356 MeV → mean range ~5.9 mm → longest range → worst resolution
BOARD TIP
▸
"The radionuclide giving the best spatial resolution in PET?"

→ F-18 (lowest positron energy → shortest range).

▸
"The worst resolution?"

→ Rb-82 (highest positron energy → longest range). Memorise: energy↑ → range↑ → resolution↓.

In a PET ring: positron range, annihilation photons, coincidence and line of response (LOR), scattered, random and multiple events, and image formation (TOF).

Continuous stream · no seeking

Key point: when two 511 keV photons are detected within the timing window the event is placed on the line joining the two detectors; scatter and randoms create false lines, and TOF narrows the position along the line.

Source: book (mean positron ranges, 180° ± 0.25° deviation, T ∝ A, R ∝ τ·A²). Ring 80 cm, to scale; event-type proportions schematic.

How to use: a single click on the drawing pauses and resumes; in the range step ↑ ↓ or the rows of the list pick the radionuclide; in the image steps drag the lesion to move it, and with TOF on ↑ ↓ change the timing resolution; ← → change steps.

Speed
Test yourself:Chapter 7 · question 2Chapter 7 · question 1
Did this animation help you understand the topic?

Figure 7.1: Maximum energy and mean positron range of positron-emitting radionuclides: as energy increases, range increases and resolution decreases.

The annihilation event:

•
After losing its kinetic energy, the positron combines with an electron
•
The mass of both particles is converted entirely into energy (mass-energy equivalence, E = mc²)
•
Two 511 keV gamma photons are produced
•
The two photons are emitted in ~180° (opposite) directions
•
Total energy: 2 × 0.511 MeV = 1.022 MeV (2 electron masses)

Acolinearity (angular deviation):

•
Ideally the two photons are emitted at exactly 180°
•
In reality the positron may have a small residual momentum at the moment of annihilation → the angle between the two photons is not exactly 180°
•
Angular deviation: ±0.25° (maximum)
•
This deviation is the second physical factor limiting the spatial resolution of PET
•
The effect of acolinearity on resolution depends on the detector diameter: ~2 mm (in a PET scanner of 80 cm diameter)
•
Acolinearity cannot be corrected → a fundamental physical limitation
BOARD TIP
▸
The two basic physical factors limiting the spatial resolution of PET: 1) positron range (depends on the energy of the radionuclide), 2) angular deviation / acolinearity (±0.25°, ~2 mm depending on detector diameter). These two factors cannot be corrected → the theoretical resolution limit of PET is ~2-3 mm.

In a PET ring: positron range, annihilation photons, coincidence and line of response (LOR), scattered, random and multiple events, and image formation (TOF).

Continuous stream · no seeking

Key point: when two 511 keV photons are detected within the timing window the event is placed on the line joining the two detectors; scatter and randoms create false lines, and TOF narrows the position along the line.

Source: book (mean positron ranges, 180° ± 0.25° deviation, T ∝ A, R ∝ τ·A²). Ring 80 cm, to scale; event-type proportions schematic.

How to use: a single click on the drawing pauses and resumes; in the range step ↑ ↓ or the rows of the list pick the radionuclide; in the image steps drag the lesion to move it, and with TOF on ↑ ↓ change the timing resolution; ← → change steps.

Speed
Did this animation help you understand the topic?

Figure 7.2: Positron emission, range, annihilation and acolinearity: the difference between the recorded LOR and the true annihilation point (schematic).

7.1.2 Coincidence Detection

The basic imaging principle of PET is based on the simultaneous (coincidence) detection of the two 511 keV photons arising from annihilation.

Coincidence principle:

•
If detectors arranged in a ring detect 511 keV photons simultaneously in two opposing detectors within a certain timing window → a coincidence event is recorded
•
The imaginary line joining these two detectors is called the LOR (line of response)
•
The annihilation event took place somewhere on this LOR
•
The location of the annihilation point is determined from the intersection of many LORs → the image is formed

Electronic collimation:

•
NO physical collimator is used in PET (the basic difference from SPECT)
•
Coincidence detection acts as electronic collimation
•
Advantages:
–
Because there is no physical collimator, sensitivity is much higher (~10-100 times that of SPECT)
–
There is no collimator-related loss of resolution
–
Better signal-to-noise ratio (SNR)
BOARD TIP
▸
"Is there a collimator in PET?"

→ NO; PET uses electronic collimation (coincidence detection).

▸
"Why is the sensitivity of PET higher than that of SPECT?"

→ No physical collimator → no photon loss → sensitivity ~10-100 times greater. This is one of the most important advantages of PET.

7.1.3 Types of Coincidence4 questions

Four types of coincidence event are defined in PET:

1. True coincidence:

–
Detection of two 511 keV photons from the same annihilation event in two opposing detectors within the timing window
–
The desired event → provides correct position information
–
True coincidence rate: T is proportional to ε² × A (independent of the timing window)
–
Note: τ affects only the random rate
–
ε: detector efficiency
–
A: activity

2. Scatter coincidence:

–
One or both of the two photons from the same annihilation event undergo Compton scattering in the patient → change direction → a wrong LOR is recorded
–
Wrong position information → loss of contrast and artefacts in the image
–
Scatter fraction: 30-40% in 3D PET (~15-20% in 2D PET)
–
Correction methods: Narrowing the energy window, model-based scatter correction (SSS – single scatter simulation)

3. Random coincidence:

–
Chance detection within the same timing window of two photons from two DIFFERENT annihilation events
–
Wrong LOR → adds homogeneous background noise
–
Random coincidence rate: R = 2 × τ × S₁ × S₂
–
τ: coincidence resolving time (the largest accepted time difference; window width 2τ)
–
S₁, S₂: singles count rates in each of the two detectors
–
Increases quadratically with activity (whereas T increases linearly) → the random/true ratio increases at high activity
–
Correction methods:
–
Delayed window method: The most common → the random rate is measured with a separate delayed timing window → subtracted
–
Narrow timing window → randoms decrease (but trues may also decrease)

4. Multiple coincidence:

–
Detection of 3 or more photons within the same timing window
–
It cannot be determined which two photons belong to the same event → the event is rejected
–
Increases at high count rates

WHY IT MATTERS · Prompt gamma

See the animation: Figure 7.3 →

•
What it is: Some positron emitters emit a gamma photon almost simultaneously with the positron. If this photon falls in the energy window, it is recorded together with one annihilation photon as if it were a true coincidence; because its timing is true, it cannot be removed with the delayed window (randoms correction).
•
In numbers: (ENSDF) I-124: β⁺ 22.7%, 603 keV gamma 62.9% (within a typical energy window of ~425-650 keV); Sc-44: 1157 keV 99.9%; Rb-82: 777 keV 15.1%; Ga-68: 1077 keV only 3.2%; F-18 is a pure positron emitter.
•
Why it matters clinically: Prompt gamma coincidences add a diffuse background to the image: without correction, activity in low-uptake regions is overestimated and contrast falls. Quantitative studies with I-124 (e.g. lesion dosimetry) and Y-86 need a separate prompt gamma correction; high-energy gammas also raise singles rates and dead time.
•
In the exam: "Why does randoms correction not remove the prompt gamma error in I-124 PET?" → Prompt gamma coincidences are in true time; they do not appear in the delayed window, so a separate correction is needed.
•
Sources: Lubberink and Herzog, Eur J Nucl Med Mol Imaging 2011; Conti and Eriksson, EJNMMI Phys 2016; ENSDF.
BOARD TIP
▸
"How do random coincidences change with activity?"

→ They increase quadratically (R ∝ A²).

▸
"True coincidences?"

→ They increase linearly (T ∝ A). For this reason the random/true ratio increases at very high activity → image quality deteriorates.

▸
"Method of random correction?"

→ The delayed window method.

In a PET ring: positron range, annihilation photons, coincidence and line of response (LOR), scattered, random and multiple events, and image formation (TOF).

Continuous stream · no seeking

Key point: when two 511 keV photons are detected within the timing window the event is placed on the line joining the two detectors; scatter and randoms create false lines, and TOF narrows the position along the line.

Source: book (mean positron ranges, 180° ± 0.25° deviation, T ∝ A, R ∝ τ·A²). Ring 80 cm, to scale; event-type proportions schematic.

How to use: a single click on the drawing pauses and resumes; in the range step ↑ ↓ or the rows of the list pick the radionuclide; in the image steps drag the lesion to move it, and with TOF on ↑ ↓ change the timing resolution; ← → change steps.

Speed
Test yourself:Chapter 7 · question 3
Read in the text:Prompt gamma
Did this animation help you understand the topic?

Figure 7.3: The four types of coincidence in PET: true, scatter, random and multiple coincidence (schematic).

7.1.4 Coincidence Timing Window

The coincidence timing window (τ) is the maximum time difference allowed for two photons to be accepted as "simultaneous".

Typical values:

•
Conventional PET: 6-12 ns (nanoseconds)
•
TOF-PET: ~3-6 ns (a narrower window is possible)
•
Energy window: In LSO/LYSO systems usually ~425/435-650 keV around the 511 keV photopeak; as the lower threshold is lowered, the accepted scatter increases

Effect of the timing window:

•
Narrow window → random coincidences↓ → noise↓ → but some true events may also be missed
•
Wide window → true events↑ → but random coincidences↑ → noise↑
•
Optimal window: The width that maximises the true/random ratio

Photons reaching two opposed detectors flow along a timeline; if a photon falls in the other detector within the window around a photon, a coincidence is recorded: true if from the same annihilation, random if from different ones. Rates by window width and activity are plotted.

Continuous stream · no seeking

Key point: true coincidences rise linearly with activity and level off once the window covers the arrival difference; randoms rise linearly with window width and with the square of activity, so noise grows at high activity and with a wide window.

Source: book (T ∝ A, R = 2τ·S₁·S₂ ∝ A², window 6–12 ns conventional, ~3–6 ns TOF; scatter 30–40% in 3D). The window width is shown as 2τ (Cherry et al.). Model: photons of one annihilation arrive at most ±2 ns apart (~60 cm patient), timing uncertainty σ 0.25 ns; singles Poisson. On the timeline the time between events is shortened for display (in reality ~10⁵–10⁶ singles/s per detector); curves relative.

How to use: a single click on the drawing pauses and resumes; ↑ ↓ change the window width in the first step and the activity in the second; ← → change steps.

Speed
Test yourself:Chapter 7 · question 3Chapter 7 · question 4
Did this animation help you understand the topic?

Figure 7.4: Variation of true, scatter and random coincidence rates with activity (A) and with the coincidence timing window (B) (schematic).

7.2 PET Detector Materials and Design

7.2.1 Scintillation Crystals2 questions

PET detectors use high-density, high-atomic-number scintillation crystals to detect 511 keV photons. The NaI(Tl) crystal used in SPECT does not have sufficient stopping power for 511 keV.

Comparison of PET crystals:

PropertyBGOLSOLYSOGSONaI(Tl)*
Density (g/cm³)7.137.407.106.713.67
Effective Z7466645951
Light output (% of NaI)15757525100
Decay time (ns)300404160230
Energy resolution (%)~20~12~12~15~8
HygroscopicNoNoNoNoYes
Suitability for TOFNoYesYesPartlyNo

NaI(Tl) is shown for reference; it is not used as standard in PET.

BGO (Bismuth Germanate – Bi₄Ge₃O₁₂):

•
Highest effective Z (74) → best stopping power → highest detection efficiency for 511 keV photons
•
Disadvantage: Very low light output (15%) and long decay time (300 ns)
•
NOT suitable for TOF-PET (slow decay)
•
The first TOF-PET systems, developed in the 1980s, used very fast BaF₂ and CsF crystals with low stopping power; TOF entered routine use only with LSO/LYSO
•
Widely used in older-generation PET scanners

LSO (Lutetium Oxyorthosilicate – Lu₂SiO₅:Ce):

•
High light output (75%) + short decay time (40 ns) → ideal for TOF-PET
•
High density (7.40) → good stopping power
•
Disadvantage: Natural Lu-176 radioactivity → low-level background counts (intrinsic radioactivity)
•
The most widely used PET crystal today

LYSO (Lutetium Yttrium Oxyorthosilicate – Lu₁.₈Y₀.₂SiO₅:Ce):

•
Properties very similar to LSO
•
Developed as an alternative to the patented LSO
•
Suitable for TOF-PET
•
Together with LSO, the most widely used PET crystals today

GSO (Gadolinium Oxyorthosilicate – Gd₂SiO₅:Ce):

•
Intermediate properties
•
Better light output and decay time than BGO
•
Lower performance than LSO/LYSO
•
Limited use
BOARD TIP
▸
"The most widely used crystal in PET?"

→ LSO/LYSO.

▸
"Highest stopping power?"

→ BGO (highest effective Z).

▸
"The most suitable crystal for TOF-PET?"

→ LSO/LYSO (short decay time ~40 ns + high light output).

▸
"Why is BGO not suitable for TOF?"

→ Long decay time (300 ns) → insufficient timing resolution.

▸
"Disadvantage of LSO?"

→ Natural Lu-176 radioactivity (intrinsic background).

suitable for TOF (fast + bright) 0 20 40 60 80 100 0 50 100 150 200 250 300 Decay time (ns) Light output (NaI = 100%) NaI(Tl)* (reference) Zeff 51 · 3.67 g/cm³ insufficient stopping power at 511 keV LSO / LYSO Zeff 66 / 64 · 7.40 / 7.10 g/cm³ most common; ideal for TOF (Lu-176 intrinsic activity) GSO Zeff 59 · 6.71 g/cm³ intermediate BGO Zeff 74 · 7.13 g/cm³ highest stopping power not suitable for TOF Circle size ∝ density · *NaI for comparison only

Figure 7.5: Relationship between light output and decay time of PET scintillation crystals; circle size is proportional to density.

Did this figure help you understand the topic?

7.2.2 Detector Design

Block detector:

•
Developed by Casey and Nutt
•
A scintillation crystal block is divided into small elements by partially cut grooves (typically 8×8 = 64 elements)
•
Optically coupled to 4 PMTs
•
Similarly to Anger logic, the crystal element in which the interaction occurred is determined from the ratios of the 4 PMT signals
•
Advantage: Many crystal elements can be read out with few PMTs → cost-effective
•
Disadvantage: Light sharing between crystal elements → limits resolution

Pixelated array:

•
Each crystal element is cut individually and isolated with reflector
•
Each element is read out independently
•
Better spatial resolution
•
Standard in current PET scanners

Detector ring design:

•
PET detectors are arranged in a full ring
•
Several rings side by side → form the axial FOV
•
Typical axial FOV: 15-26 cm (conventional PET)
•
Total-body PET: 70-200 cm axial FOV (see Section 28.4)

7.2.3 Photomultiplier Tube (PMT) and SiPM2 questions

PMT (photomultiplier tube):

•
Conventional light detector (see Section 5.2 – detailed)
•
Advantage: High gain (~10⁶), low noise
•
Disadvantage: Large size, sensitive to magnetic fields → cannot be used in PET/MR
•
Vacuum tube technology

SiPM (silicon photomultiplier):

•
Semiconductor-based light detector
•
Consists of thousands of micro-APD (avalanche photodiode) cells → each operating in Geiger mode
•
Advantages:
–
Compact size
–
Insensitive to magnetic fields → can be used in PET/MR
–
High gain (close to the PMT, ~10⁵-10⁶)
–
Excellent timing resolution → ideal for TOF-PET
–
Operates at low voltage
•
Disadvantages:
–
Temperature-sensitive → temperature control required
–
Dark current → source of noise
•
Standard today in new-generation PET and PET/MR systems
BOARD TIP
▸
"Why can PMTs not be used in PET/MR?"

→ The PMT is sensitive to magnetic fields → it cannot work in the strong magnetic field of the MR scanner.

▸
"Which light detector is used in PET/MR?"

→ The SiPM (insensitive to magnetic fields).

▸
"Advantage of the SiPM for TOF-PET?"

→ Excellent timing resolution.

A Block detector (Casey–Nutt) partial cuts → 8×8 = 64 elements γ 511 keV PMT 1 PMT 2 light sharing (2 of the 4 PMTs shown) 4 PMT signal ratio → which element (Anger logic) + few PMTs, cost-effective − light sharing → resolution limit B Pixelated array + SiPM each element isolated by reflector → independent readout SiPM reflector γ 511 keV readout electronics (low voltage) SiPM: thousands of micro-APDs (Geiger mode) + compact, gain ~10⁵–10⁶ + insensitive to magnetic field → PET/MR + excellent timing resolution → TOF − temperature-sensitive, dark current

Figure 7.6: Comparison of the block detector (Casey–Nutt) with a pixelated crystal separated by reflector and read out by SiPMs (schematic).

Did this figure help you understand the topic?

7.3 TOF-PET (Time of Flight)

7.3.1 TOF Principle

In conventional PET the difference in the arrival times of the two 511 keV photons at the detectors is not measured → the location of the annihilation point on the LOR is unknown → it is distributed with equal probability along the LOR. In TOF-PET the difference in the arrival times of the two photons at the detectors (Δt) is measured → the approximate location of the annihilation point on the LOR is calculated.

Position calculation:

Δx = (c × Δt) / 2

•
Δx: Distance of the annihilation point from the centre of the LOR
•
c: Speed of light (3 × 10⁸ m/s)
•
Δt: Difference in arrival times of the two photons

Example calculation:

•
Δt = 0 → annihilation exactly at the centre of the LOR
•
Δt = 500 ps → Δx = (3 × 10⁸ × 500 × 10⁻¹²) / 2 = 7.5 cm
•
Major manufacturers have offered TOF-PET routinely since 2006; its contribution to image quality and lesion detectability is most marked in obese patients

In a PET ring: positron range, annihilation photons, coincidence and line of response (LOR), scattered, random and multiple events, and image formation (TOF).

Continuous stream · no seeking

Key point: when two 511 keV photons are detected within the timing window the event is placed on the line joining the two detectors; scatter and randoms create false lines, and TOF narrows the position along the line.

Source: book (mean positron ranges, 180° ± 0.25° deviation, T ∝ A, R ∝ τ·A²). Ring 80 cm, to scale; event-type proportions schematic.

How to use: a single click on the drawing pauses and resumes; in the range step ↑ ↓ or the rows of the list pick the radionuclide; in the image steps drag the lesion to move it, and with TOF on ↑ ↓ change the timing resolution; ← → change steps.

Speed
Test yourself:Chapter 7 · question 7Chapter 7 · question 8
Did this animation help you understand the topic?

Figure 7.7: TOF principle: in conventional PET the event is distributed along the LOR; in TOF-PET it is assigned to a limited interval by the arrival time difference (schematic).

7.3.2 Effect of TOF on Image Quality5 questions

TOF gain:

TOF restricts the annihilation point to a certain interval (Δx) on the LOR. This increases the signal-to-noise ratio (SNR).

SNR gain formula: SNR gain ≈ √(D / Δx)

•
D: Object diameter (patient diameter)
•
Δx: TOF spatial uncertainty

Relationship between TOF timing resolution and Δx:

•
600 ps → Δx = 9 cm
•
400 ps → Δx = 6 cm
•
300 ps → Δx = 4.5 cm
•
200 ps → Δx = 3 cm
•
100 ps → Δx = 1.5 cm

Effects of TOF:

•
Increased SNR → better image quality
•
TOF does not directly improve spatial resolution (Δx is a few cm while detector resolution is at the mm level); the real gain is in effective sensitivity/SNR, contrast and lesion detectability
•
Faster iterative convergence → fewer iterations needed
•
More marked advantage in large patients (D large → gain large)
•
Improved detection of small lesions
•
Potential for dose reduction (an image of the same quality can be obtained with a lower dose)
•
Potential for shorter acquisition
BOARD TIP
▸
"The greatest advantage of TOF-PET?"

→ Increased SNR (especially in large patients).

▸
"TOF gain formula?"

→ SNR gain = √(D/Δx).

▸
"Why is the advantage of TOF greater in obese patients?"

→ D (patient diameter) is large → gain is large.

▸
"Crystal required for TOF?"

→ LSO/LYSO (short decay time).

▸
"Why is BGO not suitable for TOF?"

→ Decay time of 300 ns → insufficient timing resolution.

current systems 0 2 4 6 8 10 0 200 400 600 A 1.5 cm 3 cm 4.5 cm 6 cm 9 cm Δx = c·Δt / 2 TOF timing resolution (ps) Δx (cm) 1.0 1.5 2.0 2.5 3.0 3.5 4.0 10 20 30 40 B No TOF (gain = 1) 200 ps 400 ps 600 ps D↑ (obese patient) → gain↑ timing resolution↑ → gain↑ Patient (object) diameter D (cm) Theoretical SNR gain √(D/Δx)

Figure 7.8: Relationship between TOF timing resolution and position uncertainty (Δx) (A), and theoretical SNR gain √(D/Δx) as a function of patient diameter (B).

Did this figure help you understand the topic?

7.3.3 TOF Resolution and Clinical Advantages

Current TOF-PET systems:

•
Timing resolution: 200-400 ps (~200 ps in the best systems)
•
Δx: ~3-6 cm
•
SNR gain: ~1.5-2.5× (depending on patient size)

Technological features required for TOF:

•
Fast crystal: LSO or LYSO (decay time ~40 ns)
•
Fast light detector: SiPM (excellent timing resolution)
•
Fast electronics: High-speed signal processing
•
Precise timing calibration

Clinical advantages:

•
Better detection of small lesions
•
Improvement in low-contrast lesions
•
Marked improvement of image quality in obese patients
•
Potential dose reduction (30-50%)
•
Potential shortening of acquisition time

7.4 PET/CT Acquisition and Protocols

7.4.1 PET/CT System Design3 questions

PET/CT is a hybrid imaging system in which PET and CT components are integrated on the same gantry. The first commercial PET/CT system was introduced in 2001.

History and development:

•
The first hybrid PET/CT system was developed under the leadership of Townsend and colleagues; PET/CT entered clinical use in ~2001
•
Before PET/CT, attenuation correction was obtained with a transmission scan using external sources (e.g. a Ge-68 rod source), which could take up to 15 minutes per bed position. CT reduced this time to a few seconds and markedly increased patient throughput
•
The CTs in PET/CT systems range from 16 to 128 slices according to their intended use; protocols range from low-dose CT to contrast-enhanced, fully diagnostic CT
•
With smaller crystals, PET spatial resolution has fallen from ~7.0 mm to ~3.2 mm; this also improves count recovery and quantification
•
More than 1000 PET/CT systems in Europe and more than 3000 worldwide have been reported (in some sources the number of installed systems exceeds 6000)
•
The most widely used tracer in the world is [18F]FDG; the use of radiopharmaceuticals for neuroendocrine tumours and prostate cancer is spreading rapidly

System components:

•
CT component: Diagnostic-quality multidetector CT (MDCT)
–
Attenuation correction (CTAC)
–
Anatomical localisation
–
Diagnostic CT imaging
•
PET component: Ring detector system
–
Functional/metabolic imaging
•
Common table system: The patient moves between CT and PET on the same table
•
Software: Fusion imaging, reconstruction, correction algorithms

Acquisition sequence:

1. Topogram (scout) → scan range is defined 2. CT scan (a few seconds-minutes) → attenuation map + anatomical image 3. PET scan (1-5 minutes per bed position) → metabolic image 4. Fusion images are created

Table motion and gating:

•
Continuous table motion and adaptive table speeds make sensitivity more homogeneous along the axis and remove abrupt transitions between bed positions
•
In gated PET, coincidence events are recorded in list mode together with the gating signals
•
Cardiac gating is done with the ECG; for respiratory gating a pneumatic sensor placed in an elastic belt wrapped around the lower chest is used
•
In cardiac PET data are acquired for 10-20 minutes at a single bed position; in whole-body oncological PET the 1-3 minutes allotted to the thorax provide fewer data for respiratory gating
•
Irregular respiration and changes in its rate during the scan make correction of respiratory motion more difficult than cardiac gating

7.4.2 2D vs 3D Acquisition1 questions

2D acquisition:

•
Lead or tungsten septa are placed between the detector rings
•
Only coincidences within the same ring or between adjacent rings are accepted
•
Cross-plane coincidences are largely blocked
•
Advantages:
–
Low scatter fraction (~15-20%)
–
Low random coincidence rate
–
Simpler reconstruction
•
Disadvantages:
–
Low sensitivity (most photons are absorbed by the septa)
–
Limited axial FOV
–
No longer used today

3D acquisition:

•
The septa are removed → coincidences between all rings are accepted
•
The standard acquisition mode today
•
Advantages:
–
Sensitivity ~4-8 times higher than 2D
–
Wider axial acceptance angle
–
Better statistics → better image quality
•
Disadvantages:
–
High scatter fraction (~30-40%)
–
High random coincidence rate
–
More complex reconstruction and correction algorithms are needed
–
More data → more processing power
BOARD TIP
▸
"The standard acquisition mode in PET today?"

→ 3D (septa-less).

▸
"Change in sensitivity on going from 2D to 3D?"

→ ~4-8-fold increase.

▸
"Disadvantage of 3D?"

→ Increased scatter and random coincidences.

▸
"Function of the septa in 2D PET?"

→ To block cross-plane coincidences → reduce scatter and randoms.

An axial section shows two rows of detector rings with the patient between; annihilation photons leave at random axial angles. In 2D the septa between rings stop oblique and scattered photons; in 3D coincidences between all rings are accepted.

Continuous stream · no seeking

Key point: removing the septa lets cross-ring coincidences count and raises sensitivity ~4–8×; the price is more scatter and randoms and a more complex reconstruction.

Source: book (2D: same/adjacent ring, scatter ~15–20%; 3D: sensitivity ~4–8×, scatter ~30–40%, randoms↑). The drawing is schematic: the axial direction is stretched, so the ratio of counts in the drawing does not show the real gain. Photon directions isotropic; single scatter of ~30% of photons in the body is illustrative.

How to use: a single click on the drawing pauses and resumes; ← → switch between 2D and 3D.

Speed
Test yourself:Chapter 7 · question 16
Did this animation help you understand the topic?

Figure 7.9: Coincidence lines accepted in 2D (with septa) and 3D (septa-less) PET acquisition (schematic).

7.4.3 CT Attenuation Correction (CTAC)2 questions

In PET images the 511 keV photons are attenuated in the patient's body. Without attenuation correction, spuriously reduced uptake is seen in deep structures (e.g. the mediastinum).

CTAC principle:

1. The HU (Hounsfield unit) value of each voxel is obtained from the CT scan 2. HU values are converted into linear attenuation coefficients (µ) at 511 keV

–
The CT photon energy (~70-140 keV) differs from the PET photon energy (511 keV)
–
The bilinear scaling method is used:
–
HU ≤ 0 (soft tissue/air): One conversion curve
–
HU > 0 (soft tissue/bone): A different conversion curve

3. A 511 keV attenuation map is created 4. The PET data are corrected with this map

Advantages of CTAC (compared with a transmission source):

•
Very fast (seconds vs minutes)
•
Low-noise attenuation map
•
Simultaneous anatomical information
•
Requires no additional radiation source

Potential problems of CTAC:

•
Temporal mismatch (misregistration) between CT and PET → especially diaphragmatic motion
•
Contrast medium → falsely high µ values → hot artefact (see Section 6.5)
•
Metallic implant → streak artefact → hot artefact
•
Respiratory artefact → misregistration in the diaphragmatic region
•
Truncation artefact → if the patient's arms are outside the FOV
BOARD TIP
▸
"Why is a bilinear transformation needed in CTAC?"

→ CT photon energy (~70-140 keV) ≠ PET photon energy (511 keV) → HU values cannot be used directly → energy scaling is needed.

▸
"The common mechanism of CTAC artefacts?"

→ Falsely high HU on CT → overestimated µ at 511 keV → overcorrection for attenuation → hot artefact.

0 0.05 0.096 0.15 0.20 −1000 −500 0 500 1000 1500 2000 2500 3000 lung fat water / soft tissue bone air HU ≤ 0: air–water mixture (1st slope) HU > 0: water–bone mixture (2nd, lower slope) if a single line were used (µ overestimated in bone) Dense IV/oral contrast, metal: falsely high HU → excess µ → AC overcorrection → HOT artefact (verify with NAC image) CT value (HU) [CT photon energy ~70–140 keV] µ (511 keV), cm⁻¹

Figure 7.10: Bilinear conversion of HU into the linear attenuation coefficient at 511 keV in CTAC and the mechanism of the hot artefact caused by high HU (schematic).

Did this figure help you understand the topic?

7.4.4 FDG PET/CT Patient Preparation and Protocol5 questions

Patient preparation:

•
Fasting period: at least 4 hours (ideally 6 hours); only plain water is allowed during this time (EANM 2025)
•
Aim: To lower the insulin level → reduce FDG uptake by muscle and fat → increase tumour/normal tissue contrast
•
Blood glucose check: Blood glucose should be measured before injection
•
Threshold (EANM 2025): if plasma glucose is <11 mmol/L (~200 mg/dL) the scan is performed; if ≥11 mmol/L it should ideally be rescheduled, taking the patient's circumstances into account (in poorly controlled diabetes hyperglycaemia is not an absolute contraindication). In clinical trial protocols the upper limit may be 7-8.3 mmol/L (126-150 mg/dL). Glucose should not be below 4 mmol/L (~70 mg/dL); insulin is not given to lower glucose
–
Hyperglycaemia → FDG uptake in muscle and fat↑ → tumour uptake↓ → false negative
–
Insulin should not be given shortly before FDG because it increases muscle uptake; after short-acting insulin, wait at least 4 hours before FDG injection
–
Blood glucose regulation is important in diabetic patients
•
Hydration: About 1 L of water during the 2 hours before injection is suggested → lower urinary FDG concentration and fewer artefacts. Caffeinated drinks are not recommended; glucose-containing infusions and parenteral nutrition are stopped at least 4 hours before (EANM 2025)
•
Physical activity: Physical activity should be restricted before injection and during the uptake period → muscle uptake is reduced
•
Warm environment: Keeping the waiting room warm → reduces activation of brown adipose tissue (BAT)
•
Drug interactions:
–
Metformin → may increase bowel uptake (stopping it is controversial). SGLT2 inhibitors affect renal and bladder uptake; if this is a concern they are withheld for 48 hours before and 48 hours after the scan (EANM 2025)
–
G-CSF → increases bone marrow uptake → scan at least 2 weeks after treatment
–
Chemotherapy → at least 2-3 weeks later (ideally 6 weeks)
–
Radiotherapy → at least 2-3 months later (for inflammation to subside)

Standard FDG PET/CT protocol:

1. Patient preparation (fasting, blood glucose check)

2. FDG injection: 5-10 mCi (185-370 MBq) IV (this level applies to short axial FOV/analogue systems; on digital and long axial FOV systems a lower activity is set with the EARL procedure, EANM 2025) 3. Uptake period: 60 ± 10 minutes (in a quiet, dark, warm room) 4. Topogram (scout) 5. CT scan (low dose or diagnostic dose)

6. PET scan: In the caudal → cranial direction (to reduce urinary activity artefact)

–
Per bed position: 1-5 minutes (depending on the system)
–
Total scan time: 15-30 minutes

7. Image reconstruction and fusion

BOARD TIP
▸
"Fasting period before FDG PET/CT?"

→ At least 4 hours (ideally 6 hours).

▸
"Effect of hyperglycaemia?"

→ Muscle/fat uptake↑ → tumour uptake↓ → false negative.

▸
"Should insulin be given immediately before FDG?"

→ NO → it increases muscle uptake (FDG ≥4 hours after short-acting insulin).

▸
"Uptake period?"

→ 60 minutes.

▸
"To reduce brown fat uptake?"

→ Warm environment (starting 30-60 min before injection); results with propranolol and diazepam are conflicting.

A Standard FDG PET/CT protocol Preparation fasting ≥4–6 h (ideally 6 h) blood glucose ≤150–200 mg/dL hydration warm environment activity restriction FDG injection 185–370 MBq (5–10 mCi) IV insulin NOT GIVEN (muscle uptake ↑) Uptake (uptake period) 60 ± 10 min quiet, dark, warm room (speech/ chewing → muscle) Topogram + CT topogram: scan range CT: µ map (CTAC)+anatomy (low dose or diagnostic) PET scan caudal → cranial (urinary activity) per bed position 1–5 min total 15–30 min Reconstr. AC and NAC images + fusion B Minimum recommended wait after treatment (increased uptake → false-positive risk) G-CSF ≥2 weeks (bone marrow ↑) Chemotherapy ≥2–3 weeks, ideally 6 weeks Radiotherapy ≥2–3 months (inflammation) 0 2 4 6 8 10 12 14 weeks end of treatment = 0

Figure 7.11: Steps of the standard FDG PET/CT protocol (A) and recommended minimum waiting times after treatment (B).

Did this figure help you understand the topic?

Notes on reconstruction and quantification:

•
Attenuation correction is a prerequisite for absolute quantification (Bq/mL) in PET
•
The µ map is created by scaling the tissue electron density information obtained from CT according to the photon energy difference between PET and CT
•
The move from FBP to iterative (non-analytical) reconstruction made it possible to incorporate CT data directly into attenuation and scatter correction
•
PSF modelling (resolution recovery) changes quantitative values; harmonisation (e.g. EARL) is therefore needed in serial and multicentre studies. According to EANM 2025, EARL standards 2 is the preferred performance standard, including for long axial FOV systems

7.4.5 PET/CT Artefacts5 questions

1. CTAC-related artefacts:

–
Metallic implant artefact: CT streak artefact → falsely high HU → CTAC overcorrection → hot artefact
–
Solution: Comparison with non-attenuation-corrected (NAC) images
–
Contrast medium artefact: Dense contrast → high HU → hot artefact (especially subclavian vein, SVC)
–
Solution: CTAC with non-contrast CT or with a low-dose CT before contrast
–
Truncation artefact: Patient's arms outside the CT FOV → edge artefact
–
Solution: Positioning with arms up, extended-FOV algorithms

2. Misregistration artefacts:

–
Respiratory misregistration: Difference in diaphragm position between CT (fast, instantaneous) and PET (slow, averaged)
–
Most frequently affected region: Diaphragm base / liver dome
–
Cold artefact at the liver dome (photopenic band) or hot artefact at the lung base
–
Solution: Shallow-breathing CT, respiratory gating
–
Patient motion: Change of patient position between CT and PET
–
Solution: Patient immobilisation, short scan times

3. FDG-specific artefacts:

–
Brown adipose tissue (BAT) uptake: Symmetrical, supraclavicular, paravertebral, mediastinal
–
Increases with a cold environment and anxiety
–
Solution: Warm environment, propranolol, diazepam
–
Muscle uptake: Speaking → laryngeal muscles, chewing → masseter/pterygoid, tension → neck muscles
–
Solution: Quiet environment, muscle relaxation
–
Urinary activity: Kidney, ureter, bladder → intense physiological uptake
–
Solution: Hydration, bladder emptying, furosemide (in pelvic tumours)
–
Bowel uptake: Physiological; may be increased by metformin
–
Rebound thymic hyperplasia: In young patients after chemotherapy → diffuse FDG uptake in the thymus → false positive
BOARD TIP
▸
"Cause of a cold band artefact at the diaphragm base?"

→ Respiratory misregistration (CT in inspiration, PET at average respiration).

▸
"Symmetrical supraclavicular FDG uptake?"

→ Brown adipose tissue (BAT).

▸
"Increased uptake at the site of a metallic implant?"

→ CTAC artefact → confirm with NAC images.

▸
"Mediastinal uptake in a young patient after chemotherapy?"

→ Think of rebound thymic hyperplasia.

In a coronal section the diaphragm moves with breathing; PET sees the average of minutes of breathing, CT a single moment. The moment of the CT is chosen; the second step shows how the difference causes a cold band at the liver dome or a hot artefact at the lung base in CT attenuation correction.

Continuous stream · no seeking

Key point: CT is a snapshot, PET a breathing average; a CT in deep inspiration gives a cold band at the liver dome, a diaphragm higher than in PET a hot artefact at the lung base; CT in shallow breathing or gating prevents this.

Source: book (CT instantaneous, PET average; cold band at the liver dome or hot artefact at the lung base; solution CT in shallow breathing, respiratory gating; MRAC µ values lung 0.0224, soft tissue 0.100 cm⁻¹). Breathing curve from the Lujan et al. 1999 model (d = A·cos⁴(πt/τ), more time at expiration; mean 3/8·A). Amplitude 2 cm, period 4 s and CT positions (4/2/0 cm, shallow ≈ mean) illustrative.

How to use: a single click on the drawing pauses and resumes; ↑ ↓ or the buttons below change the breathing moment of the CT; ← → change steps.

Speed
Test yourself:Chapter 6 · question 21
Did this animation help you understand the topic?

Figure 7.12: Respiratory misregistration: the difference in diaphragm position between CT and PET producing a cold band at the liver dome (schematic).

•
When assessing PET/CT artefacts, hybrid reading that includes the non-attenuation-corrected (NAC) images is recommended
•
How to recognise a NAC image: skin and lung activity are high; the centre of the body looks faint and the periphery bright. NAC images should be reviewed for foci near metal or dense contrast, small lung nodules and suspected misregistration

7.4.6 Digital PET and Long Axial Field-of-View (LAFOV) PET1 questions

•
APD- and SiPM-based digital PET detectors provide higher sensitivity and a more compact design than PMTs
•
The better image quality of digital PET can be used for a higher detection rate, shorter scans, dynamic imaging or lower dose. New hardware and algorithms increase the need for harmonisation of quantitative values
•
The axial field of view of standard (SAFOV) PET systems is ~15-30 cm; LAFOV PET/CT systems image a region of 1-2 m simultaneously
•
LAFOV: With F-18 tracers, scanning can be performed with an exposure of ~1-2 mSv per examination, or for the whole body in well under 5 minutes; simultaneous dynamic imaging of the whole body and examination at very late time points are also possible
•
The number of LAFOV PET/CT systems in the world has been reported as ~50 and is increasing rapidly
•
Artificial intelligence may be useful in signal processing, reconstruction, advanced analysis and calculation of tumour burden, but its regulatory requirements are heavier
BOARD TIP
▸
LAFOV PET: 1-2 m axial FOV → very high sensitivity → low activity (~1-2 mSv) or very short scans (<5 min) and whole-body dynamic imaging. TOF-PET has been in routine use since 2006; the greatest gain is in obese patients.

7.5 PET/MR: Technical Features and Advantages

7.5.1 PET/MR System Design2 questions

PET/MR is a hybrid imaging system combining PET and MR components. There are two basic design approaches:

1. Simultaneous (integrated) PET/MR:

–
The PET detectors are integrated inside the MR gantry
–
PET and MR data are acquired at the same time
–
Advantages:
–
Excellent temporal co-registration (simultaneous acquisition)
–
MR data can be used for motion correction
–
Shorter total scan time
–
Technical challenges:
–
The PMT cannot work in the magnetic field → SiPMs or APDs must be used
–
PET components must not disturb MR homogeneity
–
MR RF signals must not affect the PET electronics
–
The preferred design today (e.g. Siemens Biograph mMR, GE SIGNA PET/MR)
–
Siemens' APD-based fully integrated system was launched in 2011; because the timing resolution of APDs is limited, TOF is not possible with this system
–
In 2014 GE introduced a SiPM-based, TOF-capable, fully integrated whole-body PET/MR system

2. Sequential (tandem) PET/MR:

–
PET and MR on separate gantries, connected by a common table system
–
The patient moves from one gantry to the other
–
Advantages:
–
Technically simpler (PET and MR do not affect each other)
–
Existing PET and MR technologies can be used
–
Disadvantages:
–
Temporal mismatch (sequential scanning)
–
Long total scan time
–
Risk of misregistration
–
Example: Philips Ingenuity TF PET/MR (two devices in the same room, a common table that can rotate in two planes)
–
A different solution from GE: PET/CT and MR in two adjacent rooms; the patient is transferred with a common shuttle system that can dock with both systems (tri-modality)

Digital photon counting (DPC):

•
In the digital SiPM the output of each microcell is binary: 1 if a photon was detected, 0 if not
•
Energy is found by counting the cells that fired; no analogue-to-digital conversion is needed
•
Because each crystal can be read out individually, the position-calculation arrays of block detectors are no longer needed
A Simultaneous (integrated) PET/MR PET and MR data acquired SIMULTANEOUSLY MR magnet, gradient and RF coils PET detector ring (LSO/LYSO + SiPM or APD) + excellent temporal co-registration + PET motion correction with MR, short total time − PMT cannot be used (magnetic field) → SiPM/APD − PET and MR must not interfere (B₀ homogeneity, RF) B Sequential (tandem) PET/MR Separate gantries; patient moved on a common table PET MR common (rotating) table + technically simple; existing PET and MR used − sequential scanning → temporal mismatch, risk of misregistration − long total scan time

Figure 7.13: Simultaneous (integrated) and sequential (tandem) PET/MR system designs (schematic).

Did this figure help you understand the topic?

7.5.2 MR-Based Attenuation Correction (MRAC)6 questions

Because there is no CT in PET/MR, attenuation correction must be derived from the MR data. This is the most important technical challenge of PET/MR.

The basic problem:

•
The MR signal depends on proton density and relaxation properties → it is NOT directly related to electron density
•
In CT, HU values are directly related to electron density → easily converted into an attenuation coefficient
•
In MR, bone and air are signal-free (neither gives a signal) → they cannot be distinguished → error in the attenuation map

MRAC methods:

1. Segmentation-based method (most common):

–
Tissues are classified with a Dixon sequence: air, lung, fat, soft tissue
–
A fixed µ value is assigned to each class
–
Problem: Bone cannot be segmented → attenuation is undercorrected in bone regions → spuriously reduced uptake (especially in brain PET and bone metastases)
–
4-class segmentation: Air (µ=0), lung (µ=0.0224), fat (µ=0.0854), soft tissue (µ=0.1000) cm⁻¹

2. Atlas-based method:

–
A previously created CT-MR atlas database is used
–
The patient's MR image is registered to the atlas → a pseudo-CT is created
–
Bone information is added from the atlas
–
Risk of error with anatomical variants

3. Ultrashort Echo Time (UTE) / Zero Echo Time (ZTE):

–
With a very short TE, signal can be obtained from bone
–
Bone, soft tissue and air can be distinguished
–
Used especially in brain PET/MR
–
Disadvantage: Additional scan time, limited FOV

4. Deep learning-based methods:

–
A pseudo-CT is generated from MR images with artificial intelligence
–
Can estimate all tissues, including bone
–
A promising approach

Additional points on MRAC:

•
The basic property determining the attenuation and scatter of 511 keV photons is the electron density of the tissue, whereas the MR signal reflects proton density
•
Atlas-based methods may fail when the patient's anatomy differs from the atlas (e.g. after surgery); the RESOLUTE method, developed for the head and neck, has been shown to give results consistent with the CT reference
•
Convolutional neural network-based methods learn to produce continuous-valued µ maps from structural MR images
•
MR receive coils and the patient table also attenuate 511 keV photons; they must therefore be modelled with CT-measured µ maps or designed so that their attenuation is negligible
•
In TOF-capable PET/MR, activity and attenuation can be reconstructed jointly and simultaneously (MLAA-like approaches)
•
In harmonisation with phantoms, plastic parts are invisible on MR and large volumes of water create distortion on MR; a phantom-specific, CT-derived µ map is therefore used
BOARD TIP
▸
"The most important technical challenge of PET/MR?"

→ MR-based attenuation correction (MRAC).

▸
"Why is bone a problem in MRAC?"

→ Bone gives no signal on MR → it cannot be distinguished from air → attenuation is undercorrected → spuriously reduced uptake.

▸
"The most common MRAC method?"

→ Dixon-based segmentation (4 classes: air, lung, fat, soft tissue).

▸
"Methods that solve the bone problem?"

→ UTE/ZTE, atlas-based, deep learning.

A CT-based µ map (CTAC) vertebra continuous µ values; bone a separate class (highest µ) B MRAC: Dixon 4-class segmentation vertebra bone gives no signal → soft-tissue µ assigned → attenuation undercorrected → spuriously reduced uptake µ (511 keV, cm⁻¹): air 0 lung 0.0224 fat 0.0854 soft tissue 0.1000 bone (CT only)

Figure 7.14: Comparison of a CT-based µ map with Dixon 4-class MRAC segmentation: bone classified as soft tissue (schematic).

Did this figure help you understand the topic?

7.5.3 Advantages and Limitations of PET/MR1 questions

Advantages of PET/MR over PET/CT:

•
Superior soft-tissue contrast → brain, pelvis, head and neck, liver, musculoskeletal
•
Lower radiation dose → no CT radiation → advantage in paediatric patients and repeated follow-up
•
Simultaneous acquisition → excellent temporal co-registration
•
Functional MR information → PET data can be combined with diffusion (DWI/ADC), perfusion and spectroscopy
•
Motion correction → PET correction using MR-based motion information

Limitations of PET/MR:

•
MRAC difficulties → undercorrection of bone attenuation → quantitative error
•
Lung imaging → lung parenchyma is poorly imaged on MR → CT is superior for detecting lung nodules
•
Bone lesions → cortical bone is signal-free on MR → CTAC is more accurate in bone metastases
•
Long scan time → MR scanning takes much longer than CT
•
High cost → high equipment and running costs
•
Limited availability → available in few centres
•
Claustrophobia and MR contraindications → pacemaker, metallic implant, etc.
•
Workflow complexity → expertise in both PET and MR is needed

7.5.4 Clinical Applications of PET/MR

Strong indications (advantageous over PET/CT):

•
Neurology: Dementia assessment, epilepsy, brain tumours → superior soft-tissue contrast
•
Paediatric oncology: Lower radiation dose → ALARA principle
•
Pelvic tumours: Cervix, rectum, prostate → the superior soft-tissue contrast of MR
•
Head and neck tumours: Local staging → MR superior
•
Liver lesions: Superior characterisation by MR (especially with DWI)
•
Musculoskeletal tumours: Soft-tissue sarcomas
•
Cardiac imaging: Cardiac PET/MR → perfusion + metabolism + structural assessment

Areas where PET/CT is superior:

•
Detection and characterisation of lung nodules
•
Cortical bone lesions
•
Whole-body scanning (speed and practicality)
•
Radiotherapy planning (CT-based dose calculation)

7.6 SUV Calculation and Quantitative Analysis

7.6.1 Definition and Formula of SUV

The SUV (standardised uptake value) is a semi-quantitative measure of radiopharmaceutical uptake on PET images. It normalises the activity concentration in the lesion to the injected activity and body weight.

SUV formula:

SUV = Tissue activity concentration (kBq/mL) / [Injected activity (kBq) / Body weight (g)]

Interpretation:

•
SUV = 1.0 → the radiopharmaceutical is distributed homogeneously in the body (average uptake)
•
SUV > 1.0 → uptake above average (concentration)
•
SUV < 1.0 → uptake below average
•
In malignant lesions usually SUV > 2.5 (but there is no definitive threshold)

7.6.2 SUV Variants4 questions

SUVmax (maximum SUV):

•
The single voxel with the highest SUV value within the region of interest (ROI/VOI)
•
The most widely used SUV variant
•
Advantage: Operator-independent, reproducible
•
Disadvantage: Single voxel → sensitive to noise, affected by the partial volume effect

SUVmean (mean SUV):

•
The mean SUV of all voxels within the ROI/VOI
•
Advantage: Less sensitive to noise
•
Disadvantage: ROI drawing is operator-dependent → low reproducibility

SUVpeak:

•
Mean SUV within a spherical VOI of 1 cm³ (placed over the region of highest uptake)
•
Used in the PERCIST criteria
•
Advantage: Less sensitive to noise than SUVmax and more reproducible than SUVmean

SUVlean (lean body mass SUV, SUL):

•
Normalised to lean body mass instead of body weight
•
More accurate in obese patients
•
Preferred in the PERCIST criteria

SUL = Tissue activity concentration / (Injected activity / Lean body mass)

Try it in the calculator: SUV / SUL →

SUVBSA (body surface area SUV):

•
Normalised to body surface area
•
Less widely used
BOARD TIP
▸
"The most widely used SUV variant?"

→ SUVmax.

▸
"The SUV variant used in PERCIST?"

→ SULpeak (SUVlean + peak).

▸
"Why may SUV be falsely high in an obese patient?"

→ Normalisation to body weight → fat does not take up FDG but is included in the weight → SUV is artificially raised → solution: use SUVlean.

A PET slice of a lesion is shown voxel by voxel with an SUV profile across it; SUVmax is marked as the highest voxel and SUVpeak as the mean of a 1 cm³ sphere; in the second step the threshold contour, MTV, SUVmean and TLG are computed for the chosen threshold.

Continuous stream · no seeking

Key point: SUVmax is a single voxel and sensitive to noise, SUVpeak is more stable; the partial volume effect lowers the true value of a small lesion; MTV and SUVmean depend on the threshold chosen, and TLG = MTV × SUVmean.

Source: book (SUVmax single voxel; SUVpeak 1 cm³ spherical VOI, PERCIST; SUVmean VOI average; 41% threshold MTV; TLG = MTV × SUVmean). Model (example data): 2 mm voxels, 7 mm radius sphere (true SUV 12, background 1), PET resolution FWHM 6 mm, noise illustrative (4% + 0.05). MTV is the voxels above the threshold connected to the highest voxel; TLG in SUV·mL.

How to use: a single click on the drawing pauses and resumes; in the second step ↑ ↓ change the threshold; ← → change steps.

Speed
Test yourself:Chapter 7 · question 14Chapter 7 · question 19Chapter 7 · question 18
Did this animation help you understand the topic?

Figure 7.15: The concepts of SUVmax, SUVpeak, MTV at a 41% threshold and SUVmean in a lesion; TLG = MTV × SUVmean (example data, schematic).

7.6.3 Factors Affecting SUV4 questions

SUV is affected by many technical and biological factors. Knowing these factors is critical for the correct interpretation of SUV values.

Technical factors:

•
Uptake time after injection: Time↑ → tumour SUV↑ (uptake continues) → standard: 60 min
•
Blood glucose level: Hyperglycaemia → tumour SUV↓ (competitive inhibition) → false negative
•
Extravasation: Leakage at the injection site → effective dose↓ → SUV↓ throughout the body
•
Clock calibration error: Dose calibrator and PET scanner clocks out of sync → SUV error
•
Residual activity: If the activity remaining in the syringe is not taken into account → SUV↓
•
Reconstruction parameters: Number of iterations, filter, voxel size → affect SUV
•
Partial volume effect (PVE): In small lesions (<2-3 × FWHM, ~8-10 mm) → spuriously low SUV
•
Dual-time-point imaging (~1 and 2-3 hours): the late SUV usually rises in malignant lesions. However, because it may also rise in inflammation, its value in differential diagnosis is limited

Biological factors:

•
Tumour biology: GLUT-1 expression, hexokinase activity, proliferation rate
•
Tumour size: Small tumours → PVE → low SUV
•
Necrosis: SUV may be low in necrotic tumours
•
Inflammation: Inflammatory processes increase SUV → false positive
•
Body composition: SUVbw falsely high in obese patients → SUVlean should be preferred
BOARD TIP
▸
"Factors that increase SUV?"

→ Long uptake time, inflammation, high tumour grade, granulomatous disease.

▸
"Factors that decrease SUV?"

→ Hyperglycaemia, small lesion (PVE), extravasation, short uptake time, necrosis.

▸
"When is the partial volume effect important?"

→ Lesion size < 2-3 × spatial resolution (lesions below ~8-10 mm).

7.6.4 Other Quantitative Parameters1 questions

MTV (metabolic tumour volume):

•
Tumour volume (mL) above a given SUV threshold
•
Threshold: Usually SUV ≥ 2.5 or 41% of SUVmax
•
A volumetric parameter with prognostic value

TLG (total lesion glycolysis):

•
MTV × SUVmean
•
Combines both metabolic activity and tumour volume
•
Its prognostic value may be higher than that of MTV

TLG = MTV × SUVmean

Ki (Patlak analysis / dynamic PET):

•
Calculation of the FDG metabolic rate (metabolic rate of glucose – MRGlu) from dynamic PET data
•
By Patlak graphical analysis or compartmental modelling
•
Fully quantitative measurement → more accurate than SUV but of limited use in clinical practice
•
Requires an arterial input function (invasive or image-derived)

MBF and CFR (myocardial blood flow and coronary flow reserve):

•
Measurement of absolute myocardial blood flow in cardiac PET (mL/g/min)
•
CFR = Stress MBF / Rest MBF
•
May be abnormal in balanced 3-vessel disease with an apparently normal MPI
•
Detailed information: See Section 14.7

7.7 The CT Component of Hybrid Systems: Basic Principles

7.7.1 CT Reconstruction1 questions

•
Mathematical basis: According to the Radon transform, a two-dimensional function can be recovered from its line integrals (projections)
•
The attenuation profiles collected over a full rotation of the tube and detector, arranged as an image, are called a sinogram
•
FBP was used as the standard method for about 40 years; the profiles are convolved with a kernel (the counterpart of the ramp filter in the frequency domain)
•
A smoothing kernel reduces noise but also lowers spatial resolution; an edge-enhancing kernel increases resolution but also raises noise
•
Iterative reconstruction: Reduces noise while preserving resolution, limits artefacts such as beam hardening and allows dose to be lowered
•
Drawbacks of iterative methods: Long computation time, a "plastic/pixelated" appearance and a risk of morphological change in low-contrast detail
•
Methods that denoise only in the image domain are not iterative reconstruction; they are post-processing filters
•
Statistical iterative methods model Poisson and electronic noise; model-based methods additionally take into account the focal spot, voxel/detector size, scatter and the energy spectrum
•
In hybrid systems, if CT is acquired only for attenuation correction and localisation, the dose can be reduced substantially by keeping the iterative contribution high
•
Deep learning-based reconstruction may outperform iterative methods in dose and noise reduction; however, it must be validated for detail changes that could affect diagnosis
•
HU = 1000 × (µtissue − µwater)/µwater. Typical values: water 0, air −1000, fat approximately −30 to −120, soft tissue ~+20 to +80, cortical bone ~+1000

7.7.2 CT Dosimetry and Dose Reduction4 questions

•
CTDI: An index of local absorbed dose (mGy) measured in a standard 16 cm (head) or 32 cm (body) cylindrical phantom
•
DLP = CTDI × scan length (mGy·cm); effective dose is estimated approximately by applying region-specific conversion coefficients to the DLP
•
Typical diagnostic values: CTDI ~60 mGy for the head and ~10-15 mGy for the body; DLP ~1000 mGy·cm for the skull and ~400-600 mGy·cm for the thorax/abdomen
•
CTDI is useful for comparing protocols with one another, but because it is based on a standard phantom it does not reflect the patient's actual organ dose

Automatic tube current modulation:

•
Z-axis modulation: The tube current is readjusted at each rotation according to the change in attenuation along the patient's length
•
Angular modulation: The tube current is varied within each rotation according to the difference between AP and lateral attenuation; ZXY modulation combines the two approaches
•
Organ modulation: Beam intensity is reduced when passing over anteriorly placed sensitive organs (breast, lens)
•
ECG-timed modulation: Beam intensity is reduced in cardiac phases of little use for reconstruction
•
CT parameters: As mAs increases, dose increases linearly, noise decreases (∝ 1/√mAs) and contrast is unchanged. As kVp increases, noise and contrast decrease and dose increases. Increasing pitch lowers dose. Thin slices, small pixels and a sharp kernel increase noise
•
In children kVp and mAs are lowered according to body size. In obese patients mAs/kVp are raised, pitch and rotation speed are reduced, and thicker slices and a soft kernel are preferred

7.7.3 Metal Artefact and Photon-Counting CT1 questions

•
Metal implants create data gaps in the projections; this leads to streak artefacts and loss of attenuation information in the surrounding tissue. The error may be carried into PET attenuation correction, causing activity to be over- or underestimated
•
Metal artefact reduction (MAR): Implicit methods (gantry tilt, kV/mA adjustment) or explicit software-based methods working in the sinogram or image domain
•
Photon-counting CT (PCCT): Direct-conversion semiconductor detectors (CdTe/CZT or silicon) count photons individually and sort them into groups according to their energy
•
Advantages of PCCT: The signal collection time is ~100 times shorter than with energy-integrating detectors; it gives higher resolution at the same dose or lower noise/dose at the same resolution; multi-energy spectral imaging and material decomposition are possible
•
Limitations of PCCT: Pulse pile-up, charge sharing and spurious signals from K-fluorescence

Iodine-Based Contrast Media in Hybrid Imaging

•
Hypersensitivity reactions: An immediate reaction occurs within 1 hour of administration (rarely up to 6 hours); a non-immediate reaction between 1 hour and 1 week (rarely up to 8 weeks), usually as a skin reaction
•
Severity (ACR classification): Mild → limited urticaria and pruritus, nasal congestion, sneezing. Moderate → diffuse urticaria or erythema without hypotension, facial oedema without dyspnoea, mild bronchospasm without hypoxia. Severe → facial or laryngeal oedema with dyspnoea, erythema with hypotension, bronchospasm with hypoxia, anaphylactic shock, cardiopulmonary arrest
•
First response: Stop the injection, switch the line to crystalloid and assess the patient by ABCDE. Sit the patient up for dyspnoea or stridor. In anaphylaxis call the team, give high-flow oxygen, adrenaline 0.5 mg IM (1 mg/mL; lateral upper thigh), repeated as necessary, and a crystalloid bolus
•
Observation: After a mild reaction until every symptom has gone (at least 30 min); after a greater but non-life-threatening reaction for 4-6 hours after successful treatment; admit after a life-threatening reaction. Serum tryptase is taken within 4 hours in moderate and severe immediate reactions
•
Previous reaction: Identify and record the culprit agent; if the examination is mandatory, choose a different agent. Refer moderate and severe reactions to a drug allergy specialist. A clearly indicated contrast-enhanced examination with no alternative is not refused on history alone
•
Contrast-associated acute kidney injury (CA-AKI): A rise in serum creatinine of >0.3 mg/dL, or to >1.5 times baseline, within 48-72 hours of intravascular administration. Risk threshold: eGFR <30 mL/min/1.73 m² for intravenous administration; eGFR <45 for intra-arterial administration with first-pass renal exposure and for intensive-care patients
•
Prevention: Low- or iso-osmolar agent at the lowest diagnostic dose; intravenous hydration (saline or bicarbonate) in at-risk patients. Oral hydration alone is not sufficient; no drug has shown consistent protection
•
Metformin: With eGFR >30 and no acute kidney injury, metformin is continued for intravenous contrast. With eGFR <30, acute kidney injury or first-pass intra-arterial administration, metformin is stopped at the time of contrast; eGFR is measured within 48 hours and metformin restarted if renal function is unchanged
•
Thyroid: Iodine-based contrast is not given in manifest hyperthyroidism. Patients at risk of iodine-induced hyperthyroidism are those with untreated Graves' disease and those with multinodular goitre and autonomy, especially if elderly or living in an iodine-deficient area
•
Dialysis: There is no need to time the injection to the dialysis session or to add a session for iodine-based contrast

Incidental Findings on the CT Component of Hybrid Imaging

•
Prior imaging (even of a different type, such as CT, PET/CT, ultrasound or lumbar MRI) should always be compared when available to establish stability. Some features suggesting malignancy may not be visible on low-dose unenhanced CT
•
Pulmonary nodule (Fleischner 2017): applies to patients aged 35 or over without a history of cancer or immunosuppression, outside screening. Single solid nodule <6 mm: no routine follow-up in low-risk patients (in high-risk patients with suspicious morphology or upper lobe location, CT at 12 months may be considered); 6-8 mm: CT at 6-12 months (in high-risk patients also at 18-24 months); >8 mm: CT at 3 months, PET/CT, tissue sampling or a combination
•
–
Pure ground-glass nodule ≥6 mm: CT at 6-12 months, then every 2 years until 5 years. Part-solid nodule ≥6 mm: CT at 3-6 months, then annually for at least 5 years if persistent; for a solid component >8 mm or a growing solid component, PET/CT, biopsy or resection. Size is the average of the long and short axes
•
Adrenal mass (ACR 2017): macroscopic fat (myelolipoma), ≤10 HU on unenhanced CT or signal loss on chemical-shift MRI → no further imaging needed (lipid-rich adenoma). A mass stable for at least 1 year is very likely benign. In an indeterminate 1-4 cm mass, absolute washout ≥60% or relative washout ≥40% on adrenal protocol CT is diagnostic of an adenoma. For an enlarging mass in a patient with a cancer history, PET/CT or biopsy; for an indeterminate mass ≥4 cm in a patient without a cancer history, resection (without biopsy) is recommended
•
Thyroid nodule (ACR 2015): thyroid ultrasound is recommended if CT or MRI shows suspicious features (invasion of local tissues, abnormal lymph nodes) or if the nodule is ≥1 cm in patients under 35 or ≥1.5 cm in patients aged 35 or over. A nodule with focal FDG uptake on PET should have ultrasound, and fine-needle aspiration is recommended regardless of the ultrasound findings; diffuse thyroid uptake without a mass is not considered focal. Patients with limited life expectancy or serious comorbidities are not evaluated further unless clinically warranted
BOARD TIP
▸
CTDI shows the local dose in the phantom, not the patient dose. DLP = CTDI × scan length; for an estimate of effective dose, DLP is multiplied by a conversion coefficient. Smoothing kernel: noise↓, resolution↓. Iterative reconstruction: noise↓, resolution preserved → dose↓.
BOARD TIP
▸
"First drug and route in anaphylaxis after contrast?"

→ Adrenaline 0.5 mg, intramuscular (lateral upper thigh).

▸
"eGFR threshold for renal risk with intravenous iodine-based contrast?"

→ <30 mL/min/1.73 m².

▸
"Metformin before intravenous contrast in a diabetic patient with an eGFR of 50?"

→ It is continued.

BOARD TIP
▸
"Incidental 5 mm solid pulmonary nodule in a low-risk patient (Fleischner 2017)?"

→ No routine follow-up is needed.

▸
"Adrenal mass of 10 HU or less on unenhanced CT?"

→ Lipid-rich adenoma; no further imaging is needed.

7.8 The MR Component of PET/MR: Basic Principles

7.8.1 Nuclear Magnetic Resonance and Image Formation

•
Nuclei with an odd number of protons and/or neutrons (e.g. ¹H) possess spin angular momentum and a magnetic moment
•
Spins placed in a static B₀ field produce a net magnetisation; tipped into the transverse plane by RF excitation, this magnetisation precesses at the Larmor frequency
•
The NMR phenomenon was discovered in 1946 by Bloch and Purcell
•
Larmor frequency: ω = γB₀; it becomes position-dependent when gradients are added: ω(r) = γB₀ + γG·r
•
Slice selection: While a gradient is applied, only spins falling within the bandwidth of the RF pulse are excited (sinc-shaped pulse → near-rectangular slice profile)
•
k-space (k = γGt) is filled with the frequency-encoding (readout) and phase-encoding gradients; the image in real space is obtained by applying a Fourier transform
•
Soft-tissue contrast depends on the excitation timing, the flip angle and the T1 (longitudinal) and T2 (transverse) relaxation properties of the tissue

7.8.2 MR Scanner Components

•
Three basic components: The magnet, the gradient coils and the RF (transmit/receive) coils
•
Clinical systems mostly use 1.5-3 T superconducting magnets; B₀ homogeneity is kept below 4 ppm within a spherical volume of ~50 cm diameter
•
The x, y and z gradients serve both for spatial encoding and for shimming
•
Phased-array receive coils speed up imaging. PET/MR coils must be designed with little material to minimise RF interference with the PET electronics and photon attenuation
•
Deep learning-based reconstruction shortens scanning by obtaining high-quality images from undersampled k-space (e.g. AIR Recon DL, Deep Resolve, AiCE)
•
Because PET/MR involves no CT radiation, it is advantageous especially in children and patients of reproductive age

MR Spectroscopy

•
Proton MR spectroscopy shows the metabolites in a selected volume by the chemical shift (ppm) of their resonance frequencies; a spectrum can be obtained from a single voxel or a metabolite map across a volume
•
Main peaks: NAA 2.0 ppm (neuronal marker; the largest peak in normal brain), creatine 3.0 ppm (energy store, relatively stable), choline 3.2 ppm (membrane turnover; an increase reflects cell proliferation), myo-inositol ~3.6 ppm (seen at short TE), lactate 1.3 ppm doublet (anaerobic glycolysis), lipids 0.9-1.3 ppm (necrosis)
•
At a TE of 135-144 ms the lactate doublet is inverted (J-coupling), which separates it from lipids at the same position. More metabolites are seen at short TE
•
Brain tumours: choline rises and NAA falls; the choline/NAA ratio is used. A reduced NAA is not specific to tumours (stroke, multiple sclerosis). After treatment, high choline/NAA and choline/creatine ratios suggest recurrence; reduced NAA and a lipid peak may be present in both recurrence and radiation necrosis

Gadolinium-Based Contrast Agents

•
At approved doses the risk of acute kidney injury with gadolinium-based agents is extremely low; the main concern in renal failure is nephrogenic systemic fibrosis (NSF)
•
NSF risk classes: Highest → the linear agents gadodiamide, gadopentetate and gadoversetamide (intravenous use suspended by the European Medicines Agency, or the product withdrawn). Intermediate → gadobenate and gadoxetate (approved for hepatobiliary imaging only). Lowest → macrocyclic agents (gadobutrol, gadoterate, gadoteridol, gadopiclenol)
•
Lowest-risk agents: Measuring eGFR beforehand is not mandatory; with known or suspected GFR <30 mL/min the decision follows a risk-benefit assessment
•
No special precaution is needed for gadolinium-based agents in patients on metformin
•
Immediate dialysis is not needed after a macrocyclic agent

MR Safety

•
Three fields, three risks: The static magnetic field (B₀) attracts and twists ferromagnetic objects → projectile effect. The radiofrequency field (B₁) heats tissue and conductors → burns. Time-varying gradient fields cause peripheral nerve stimulation and loud acoustic noise (hearing protection is needed)
•
Safety zones: The facility is divided into four zones. Zone IV is the scanner room, where there is a potentially lethal projectile risk. Zone III is the access-restricted area leading to Zone IV; everyone entering Zones III and IV is screened (including with a ferromagnetic detector)
•
Labels: MR Safe (green square) → a non-metallic, non-conducting, non-magnetic object; no hazard in any MR environment. MR Conditional (yellow triangle) → safe only under the stated conditions. MR Unsafe (red circle) → unacceptable risk. A conditional label applies only to the stated field strength: a device conditional at 3 T cannot be assumed safe at 1.5 T or 7 T
•
RF heating: SAR estimates the rate of absorption of RF energy. In Normal Operating Mode the whole-body averaged SAR is ≤2 W/kg; this limits whole-body heating but does not eliminate the risk of burns (the patient is padded from the bore and cables, and cable loops are avoided). Abandoned or retained conducting leads can heat seriously at their tips within seconds
•
Quench (emergency magnet off): The rapid expansion and venting of cryogen in a superconducting magnet. It is used when a person is pinned to the magnet or cannot otherwise be removed safely; the room is evacuated immediately. If venting fails, cryogen gas can fill the room (white cloud; risk of asphyxia and frostbite)
•
Pregnancy: MR up to 3 T in Normal Operating Mode may be performed when benefit to the patient or fetus is expected and the information cannot practically be obtained otherwise
•
PET/MR: Emergency procedures should cover radioactive spills as well as quench
Safety zones Zone III access-restricted area everyone entering is screened Zone IV scanner room potentially lethal projectile risk ferromagnetic detector and screening Labels MR MR Safe non-metallic, non-conducting, non-magnetic; no hazard in any MR environment MR MR Conditional safe only under the stated conditions; does not carry over to another field strength MR MR Unsafe unacceptable risk in the MR environment

Figure 7.15a: MR safety zones (Zones III and IV) and MR safety labels (schematic).

7.9 Comparison of Imaging Modalities1 questions

Which modality is chosen depends on the clinical question to be answered. The resolution values in the comparison below belong to preclinical (small-animal) systems; in clinical CT and MR spatial resolution is approximately 0.5-1 mm:

ModalitySpatial resolutionTemporal resolutionSensitivity (molar)Main target
PETmmseconds-minutes10⁻¹¹-10⁻¹²Physiology, molecular
SPECTmm-cmminutes10⁻¹⁰-10⁻¹¹Physiology, molecular
MRI10-250 µmmilliseconds10⁻³-10⁻⁵Anatomy, physiology, molecular
CT~50 µmseconds-minutes– (relative)Anatomy, physiology
Ultrasound30-500 µmmilliseconds-minutes10⁻⁶-10⁻⁹Anatomy, physiology
Optical (fluorescence)2-3 mmseconds-minuteshigh (depth limited to mm)Molecular
•
Hybrid imaging: Dual-modality systems combining structural and functional imaging (SPECT/CT, PET/CT, PET/MR) are the most widely accepted approach
•
The first SPECT/CT prototypes appeared in the early 1990s and PET/CT (Townsend and Beyer) in the late 1990s and early 2000s; PET/MR entered clinical use about a decade later
•
Even when combined on a single table, tri-modality systems have not gone beyond the proof-of-principle stage because imaging is sequential
BOARD TIP
▸
Ranking by molecular sensitivity: PET (picomolar, 10⁻¹¹-10⁻¹²) > SPECT (10⁻¹⁰-10⁻¹¹) >> MRI (millimolar-micromolar). Ranking by spatial resolution: CT/MR >> PET (mm) > SPECT (mm-cm); CT and MR are sub-millimetre clinically and at the µm level in preclinical systems.

Key Points for the Board

Additional Points – PET/CT, PET/MR, CT and MR

•
PET/CT ~2001 (Townsend); CT replaced the Ge-68 transmission scan, which took up to 15 min
•
TOF routine since 2006; LAFOV 1-2 m → ~1-2 mSv or <5 min whole body
•
Gating: list mode; cardiac → ECG, respiratory → pneumatic belt
•
PET/MR: Siemens 2011 (APD, no TOF), GE 2014 (SiPM, with TOF)
•
DPC: SiPM microcell binary output; energy = number of cells fired
•
MR coils and the table also contribute to 511 keV attenuation; CT-derived µ map in the phantom
•
CTDI (16/32 cm phantom, mGy) ≠ patient dose; DLP = CTDI × length
•
Iterative reconstruction → noise↓, resolution preserved, dose↓; PCCT → photon counting, spectral imaging
•
MR: ω = γB₀; clinical 1.5-3 T; k-space → Fourier transform
•
Molecular sensitivity: PET > SPECT >> MRI

Annihilation Physics – Critical Numbers

•
Threshold energy for positron emission: 1.022 MeV
•
Annihilation photon energy: 511 keV (each)
•
Total annihilation energy: 1.022 MeV
•
Angle between the two photons: ~180°
•
Angular deviation (acolinearity): ±0.25°
•
Effect of acolinearity on resolution: ~2 mm (in a PET of 80 cm diameter)
•
Theoretical resolution limit of PET: ~2-3 mm

Positron Range – Quick Memory Table

•
F-18: 0.6 mm → BEST resolution
•
C-11: 1.1 mm
•
N-13: 1.5 mm
•
O-15: 2.5 mm
•
Ga-68: 2.9 mm
•
Rb-82: 5.9 mm → WORST resolution
•
Rule to memorise: energy↑ → range↑ → resolution↓

Types of Coincidence – Quick Comparison

•
True: Same event, correct LOR → the desired event
•
Scatter: Same event, scattered photon → wrong LOR → loss of contrast
•
Random: Different events, chance pairing → wrong LOR → homogeneous noise
•
Multiple: 3+ photons at once → event rejected
•
Random correction method: Delayed window
•
Random ∝ A² (quadratic), True ∝ A (linear)

PET Crystals – Quick Memory Points

•
Highest stopping power: BGO (highest effective Z)
•
Most widely used: LSO / LYSO
•
Most suitable for TOF-PET: LSO / LYSO (short decay time ~40 ns)
•
Why BGO is not suitable for TOF: Long decay time (300 ns)
•
Disadvantage of LSO: Natural Lu-176 radioactivity (intrinsic background)
•
Best energy resolution: NaI(Tl) (~8%) → but insufficient stopping power for PET
•
Light detector in PET/MR: SiPM (insensitive to magnetic fields)
•
Why PMTs cannot be used in PET/MR: Sensitive to magnetic fields

PET vs SPECT – Basic Differences

•
PET: Electronic collimation (coincidence detection) → NO physical collimator
•
SPECT: Physical collimator required
•
PET sensitivity ~10-100 times higher than SPECT
•
PET spatial resolution: ~4-6 mm (clinical) vs SPECT: ~8-12 mm
•
PET: 511 keV photons vs SPECT: the gamma energy of the radionuclide (usually 70-364 keV)

TOF-PET – Critical Formulas and Concepts

•
Position calculation: Δx = c × Δt / 2
•
SNR gain: √(D / Δx)
•
Most marked advantage in obese patients (D large → gain large)
•
Required for TOF: Fast crystal (LSO/LYSO) + SiPM + fast electronics
•
Current timing resolution: 200-400 ps
•
200 ps → Δx = 3 cm
•
400 ps → Δx = 6 cm
•
TOF does not directly improve spatial resolution (Δx is at the cm level); the gain is in SNR/effective sensitivity, contrast and lesion detectability
•
PET energy window typically ~425/435-650 keV (LSO/LYSO); if the lower threshold is lowered, scatter acceptance increases

CTAC – Critical Points

•
Bilinear transformation: conversion from CT energy (~70-140 keV) to the µ value at 511 keV
•
SUVbw falsely high in an obese patient → solution: SUVlean
•
HU > 0: Different curve (soft tissue-bone)
•
Metallic implant → falsely high HU → CTAC overcorrection → hot artefact
•
Contrast medium → falsely high HU → hot artefact
•
Respiratory misregistration → cold band at the diaphragm base or hot artefact at the lung base
•
Verification: Always compare with NAC (non-attenuation-corrected) images
•
NAC image: skin and lung activity high, centre of the body faint/periphery bright
•
CT parameters: mAs↑ → dose↑ linearly, noise ∝ 1/√mAs, contrast unchanged; kVp↑ → noise↓, contrast↓, dose↑; pitch↑ → dose↓

PET/MR – Critical Points

•
Most important technical challenge: MRAC (MR-based attenuation correction)
•
The MRAC problem: bone and air are signal-free on MR → cannot be distinguished → bone attenuation is undercorrected
•
Most common MRAC method: Dixon-based segmentation (4 classes: air, lung, fat, soft tissue)
•
Methods that solve the bone problem: UTE/ZTE, atlas-based, deep learning
•
Light detector in PET/MR: SiPM (the PMT cannot work in the magnetic field)
•
Advantages of PET/MR: Superior soft-tissue contrast, lower radiation dose, simultaneous acquisition, functional MR
•
Areas where PET/CT is superior: Lung nodules, cortical bone lesions, speed/practicality, RT planning
•
Strong indications for PET/MR: Neurology, paediatric oncology, pelvic tumours, head and neck, liver

SUV – Critical Points

•
SUV formula: Tissue activity concentration / (Injected activity / Body weight)
•
Most common variant: SUVmax (single voxel, operator-independent)
•
PERCIST variant: SULpeak (lean body mass + 1 cm³ spherical VOI)
•
"Why is SUV falsely high in an obese patient?" → Fat does not take up FDG but is included in the weight → use SUVlean
•
Increases SUV: Long uptake time, inflammation, high tumour grade
•
Decreases SUV: Hyperglycaemia (the most important!), small lesion (PVE), extravasation, short uptake time
•
Partial volume effect: Lesion < 2-3 × resolution (~8-10 mm) → SUV lower than it is
•
TLG = MTV × SUVmean
•
Standard uptake time: 60 ± 10 minutes
•
Dual-time-point imaging: the late SUV usually rises in malignancy, but it also rises in inflammation → limited value in differentiation

FDG PET/CT Patient Preparation – Exam Favourites

•
Fasting: Minimum 4-6 hours
•
Upper limit of blood glucose: 150-200 mg/dL
•
Hyperglycaemia → tumour SUV↓ → false negative
•
Insulin should not be given immediately before FDG → muscle uptake↑ (FDG ≥4 hours after short-acting insulin)
•
Reducing brown fat (BAT): Warm environment, propranolol, diazepam
•
BAT locations: Supraclavicular, cervical, paravertebral, mediastinal → bilateral symmetrical
•
After G-CSF: Wait at least 2 weeks (bone marrow uptake)
•
After chemotherapy: At least 2-3 weeks (ideally 6 weeks)
•
After radiotherapy: At least 2-3 months
•
Rebound thymic hyperplasia: Diffuse mediastinal uptake in a young patient after chemotherapy → false positive

2D vs 3D PET – Quick Comparison

•
2D: Septa present → scatter↓, randoms↓ → but sensitivity↓ → no longer used
•
3D: No septa → sensitivity ~4-8-fold↑ → but scatter↑ (30-40%), randoms↑ → the standard today

Comparisons Frequently Asked in the Exam

•
"Is there a collimator in PET?" → NO (electronic collimation)
•
"With which radionuclide is PET resolution best?" → F-18
•
"With which radionuclide is PET resolution worst?" → Rb-82
•
"Why is TOF more advantageous in an obese patient?" → D large → √(D/Δx) large
•
"How do you verify a CTAC artefact?" → Compare with NAC images
•
"Why is bone a problem in PET/MR?" → Bone is signal-free on MR → confused with air → undercorrection
•
"What happens in hyperglycaemia?" → Tumour SUV↓ → false negative
•
HU ≤ 0: One curve (air-soft tissue)

Current guidelines on this chapter's topics

The latest guidelines and consensus documents on the procedures covered in this chapter (official EANM index and primary sources, November 2026). Comparison of the text with these versions is in progress; consult the guideline itself for details.

  1. 2025[18F]FDG PET/CT: EANM procedure guidelines for tumour imaging: version 3.0 (opens in a new tab)
  2. 2023International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology (opens in a new tab)
  3. 2022EANM guidelines for PET-CT and PET-MR routine quality control (opens in a new tab)
  4. 2017Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017 (opens in a new tab)

Finished the chapter?

This chapter has 27 questions. Solve them now to consolidate the topic.

Solve questions →
Previous chapterGamma Camera and SPECT/CTNext chapterImage Reconstruction and Processing

You can also swipe sideways to change chapter

After leaving the nucleus the positron follows a tortuous path in tissue until it loses its energy; this distance is the positron range. Compare the ranges of six radionuclides on the left and watch the selected positron in the magnified panel: higher energy means longer range and poorer resolution (F-18 ~0.6 mm, Rb-82 ~5.9 mm).

Mean positron range (in tissue)F-180.6 mm · Emax 0.634 MeVC-111.1 mm · Emax 0.96 MeVN-131.5 mm · Emax 1.198 MeVO-152.5 mm · Emax 1.732 MeVGa-682.9 mm · Emax 1.899 MeVRb-825.9 mm · Emax 3.382 MeVTap a row: its positron appears on the right
Patient cross-section
F-18 positronEmax 0.634 MeV · ~0.6 mm5 mm
Positron path in tissue at the same magnification for all radionuclides; dashed circle = mean range.

Step 1/2

Annihilation

Once its energy is spent the positron combines with an electron; the mass of both particles turns into two 511 keV photons emitted ~180° apart (non-collinearity ±0.25°). PET sees this annihilation point, not the point where the positron was emitted.

Patient cross-section
F-18 positronEmax 0.634 MeV · ~0.6 mm5 mm
Positron path in tissue at the same magnification for all radionuclides; dashed circle = mean range.

Besides true events there are three more types. Scatter: one photon changes direction by Compton scattering in the patient. Random: one photon each from two different annihilations falls into the same window. In both the LOR misses the true annihilation point and adds false information. Multiple: 3 or more photons are detected in the same window; the pair cannot be identified and the event is rejected. Randoms and multiples increase at high count rates (R ∝ A²).

 

Patient cross-section

Step 1/2

Timing window

When a photon reaches a detector, the electronics open a short timing window around it (2τ). If exactly one photon falls in the opposite detector within this window, a coincidence is recorded. If both photons come from the same annihilation it is a true coincidence (solid line); if photons from other annihilations fall into the window by chance it is a random coincidence (dashed). A narrower window cuts randoms but also loses true pairs with a larger arrival difference.

Coincidence timing windowDetector 1Detector 2True: 7 · Random: 2Random / true = 0.29photon from the same annihilationphoton whose partner was losttime between events shortened
Rates by window width02468101214window width 2τ (ns)coincidence rate (relative)true (T)random (R) ∝ 2τExample: S₁ = S₂ = 1 Mcps, 2τ = 6 ns → R = 6 kcps

Step 1/2

Image formation and TOF

As many LORs build up, the lesion where the radiopharmaceutical accumulates becomes visible; the image is reconstructed from these data. Turn on TOF: the arrival time difference limits the annihilation to a segment Δx = c·Δt/2 on the LOR, so the lesion appears sooner (SNR gain ≈ √(D/Δx)).

LesionPatient cross-sectionTap inside the patient to move the lesion
Image forming0 LORs · TOF offUnfiltered backprojection

A lesion is a focus where the radiopharmaceutical is taken up more than the surrounding tissue (e.g. an FDG-avid tumour). Some annihilations occur there and the rest in normal tissue. As LORs accumulate the lesion becomes visible; the PET image is reconstructed from this accumulation (more distinct with TOF). Drag the lesion to move it and change its uptake below.

True
0
Scatter
0
Random
0
True coincidence fraction
—

The ring is to scale (80 cm diameter); the positron path is magnified in a separate panel. Event-type proportions are schematic; the dependencies follow the book (T ∝ A, R ∝ τ·A², scatter ~30-40% in 3D PET).

Step 1/2

2D (septa)

Lead or tungsten septa sit between the rings. Photons travelling obliquely hit a septum and are absorbed; only pairs reaching the same or an adjacent ring are recorded. Most photons scattered in the patient also stop in the septa: scatter and randoms are low, but because most photons are lost, sensitivity is low.

2D acquisition (with septa)patientCoincidences accepted: 12septa (lead/tungsten)axial direction →
2D and 3D compared2D3DBetween ringssame/adjacentallSensitivitylow~4–8×Scatter fraction~15–20%~30–40%RandomslowhighReconstructionsimplecomplextrue LORscattered (wrong LOR)Schematic; axial direction stretched. Values from the book.

Step 1/2

PET average, CT moment

The diaphragm moves up and down with each breath, staying longer at end-expiration. PET collects a bed position over minutes and sees the average diaphragm position. CT is taken in seconds and catches a single moment of breathing. Choose when the CT was taken: the gap between the two lines is the misregistration.

Breathing: PET average and CT momentlungliverrightleft
Diaphragm position0123404812time (s)diaphragm (cm, down)end-expiration = 0PET: average over minutesCT: a single moment

Step 1/2

SUVmax and SUVpeak

The lesion's true SUV is 12, but PET's limited resolution blurs a small lesion and lowers its peak value (partial volume effect). SUVmax is the single highest voxel: easy and reproducible, but sensitive to noise. SUVpeak is the highest mean of a 1 cm³ sphere: less affected by noise; it is used in PERCIST.

SUVmax and SUVpeak1 cmtrue: 14 mm sphere, SUV 12SUVmax11.5
SUV profile across the lesion024681012−20−1001020position (mm)SUVbackground ~1SUVmax